Equities

Dali Pharmaceutical Co Ltd

603963:SHH

Dali Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)4.97
  • Today's Change-0.23 / -4.42%
  • Shares traded13.82m
  • 1 Year change-55.39%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dali Pharmaceutical Co Ltd is a China-based company principally involved in the production and sales of Chinese and western medicine injections. The Company’s main products include Xingnaojing injections and Shenmai injections. The other products include astragalus injections and mycorrhizal injections. Through its subsidiaries, the Company is also involved in the lease of offices and factory buildings, as well as the investment of equity.

  • Revenue in CNY (TTM)65.70m
  • Net income in CNY-22.85m
  • Incorporated1996
  • Employees272.00
  • Location
    Dali Pharmaceutical Co LtdNo.118, Huancheng West Road, XiaguanDALI 671000ChinaCHN
  • Phone+86 8 728880055
  • Fax+86 8 728880055
  • Websitehttp://www.daliyaoye.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hangzhou Tianmushan Phrmtcl ntrprs C Ltd137.86m-38.94m994.93m380.00--36.29--7.22-0.3198-0.31981.130.22510.46192.303.90362,781.80-13.21-6.93-54.44-18.9221.1633.95-28.59-16.420.5282-4.370.6609--11.82-19.4243.35---24.89--
Dali Pharmaceutical Co Ltd65.70m-22.85m1.09bn272.00--2.91--16.62-0.104-0.1040.29911.710.13811.1515.89241,555.10-4.80-2.31-5.61-2.7722.1665.39-34.78-7.003.11--0.0593---34.06-26.30-13.16--16.34--
AVE Science & Technology Co Ltd206.22m24.46m1.17bn492.0047.652.36--5.650.35970.35973.037.280.37952.0433.65419,148.404.507.214.928.1855.6958.9311.8615.485.60--0.0022.461.795.8819.81-4.62-23.68--
Shanghai Rendu Biotechnology Co Ltd180.85m-8.77m1.35bn528.00--1.42--7.49-0.2192-0.21924.5223.780.16951.821.99342,521.40-0.8215---0.8869--70.19---4.85--13.78--0.008--3.95---63.89------
Shaanxi Kanghui Pharmaceutical Co Ltd588.60m-70.10m1.44bn828.00--1.46--2.44-0.7018-0.70185.899.840.2892.233.02710,868.00-4.511.41-6.351.7130.4145.74-15.604.480.8839-2.790.403432.3411.016.01-272.84--107.49--
Shanghai Rightongene Biotechnlgy Co Ltd265.52m7.17m1.44bn501.00194.101.55--5.440.13320.13324.7516.670.25401.091.40529,970.30-0.09014.16-0.0984.4975.0270.45-0.354811.6210.43--0.02845.90-39.142.84-80.41-11.4619.65--
Shanghai Serum Bio-Technology Co Ltd192.49m37.23m1.60bn321.0042.961.47--8.310.34410.34411.7810.050.16890.92826.82599,656.403.2710.433.3210.8475.0880.5419.3432.5750.03--0.011964.939.145.67-39.54-1.6213.07--
Data as of May 17 2024. Currency figures normalised to Dali Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.28%Per cent of shares held by top holders
HolderShares% Held
Western Leadbank Fund Management Co., Ltdas of 31 Dec 2023242.10k0.19%
Hongde Fund Management Co., Ltd.as of 31 Dec 2023119.10k0.09%
Lion Fund Management Co., Ltd.as of 30 Jun 202339.000.00%
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.